Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
TRANSCAN-2 has the goal of coordinating national and regional funding programmes for research in the area of translational cancer research. The specific challenge is to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research while avoiding the duplication of efforts and ensuring a more efficient use of available resources, to produce significant results of higher quality and impact, and share data and infrastructures.
The EC co-funded call of TRANSCAN-2 (JTC 2017) will focus on: “Translational research on rare cancers”
Característiques principals
The proposals of the present call will have to cover a minimum of one of the specific aims reported below:
  • Aim 1: Design and conduct of translational research studies exploiting/combining resources from current clinical trials, bio-repositories and epidemiology-type resources.
  • Aim 2: Development and exploitation of translational research platforms (e.g., patient derived xenograft models/organoids/tissue collections) to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs.
  • Aim 3: Implementation of precision biomarkers for better stratification of the clinical cohorts.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://www.transcanfp7.eu/index.php/calls/fourth-joint-transnational-call-jtc-2017.html
    Informació addicional
    Aplicatiu web:
    http://transcan.cbim.it/
    Requisits
    Only transnational projects will be funded. Each research consortium must involve a minimum of three (3) research groups and a maximum of seven (7) research groups. The groups must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from one country (in such cases the minimum number of groups must be 4, coming from 3 different countries). The maximum number of 7 research groups could be increased only with partners from the following countries : Estonia, Latvia, Slovakia and Turkey, up to a maximum of 4 additional partners from the 4 countries, to reach a maximum total of 11 research groups in a proposal.

    In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, Slovakia and Turkey.

    Each consortium must involve at least one basic or pre-clinical research team and one clinical team.

    Plase check the Call Text for detailed eligibility rules.

    For Spanish applicants: please check the eligibility requirements of the institution and the principal investigator/team members, in pages 56-59 of the Call Text.
    Dotació
    For Spanish participants:
  • up to 150,000 € (overheads included) per partner
  • up to 200.000 € (overheads included) per coordinator
    • Durada
    3 years
    AVÍS IMPORTANT
    En cas de voler presentar-vos a la convocatòria, per favor no contacteu directament amb ISCIII/AECC, dirigiu-vos al Servei de Recerca (Carol Barnwell / Marta López).

    Arxius

    Arxiu
    TRANSCAN-2_Guidelines_for_applicants_JTC-2017.pdf
    TRANSCAN-2_Call_text_JTC-2017_rev13_12_2017.pdf
    20170412_PreProposal_JTC2017_fillable.pdf